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A number of studies have shown elevated matrix
metalloproteinase expression in chronic wound ¯uid
compared to an acute wound; however, little has
been done to characterize animal models in a similar
manner and thus determine their usefulness. The
diabetes mouse is an animal model of type II diabetes
that shows impaired dermal wound healing and has
been proposed as a model of human impaired
wound healing. In this study we have determined the
mRNA and protein expression pro®les of matrix
metalloproteinases 2, 3, and 9 during the ®rst 10 d of
dermal healing for the diabetes mouse and its nor-
mally healing littermate. Additionally, human wound
¯uid from diabetic chronic wounds and acute surgi-
cal wounds were studied to enable a comparison of
the model to the human condition. We show that
during the early stages of wound healing the diabetes
mouse possesses signi®cantly reduced protein levels
of pro-matrix metalloproteinases 2 and 9 within the
wound tissue and active matrix metalloproteinase 3
within the ¯uid. Pro-matrix metalloproteinase 3
levels are also signi®cantly reduced in the diabetes
mouse during the later stages of healing. These
differences may be contributing to the impaired
healing of the diabetes mouse; however, they differ
from the human data presented here, which show
elevated matrix metalloproteinase 2 and reduced
matrix metalloproteinase 9 in human diabetic
chronic wound ¯uid compared to acute wound ¯uid.
Therefore, although clearly showing the importance
of appropriate matrix metalloproteinase regulation
for normal acute wound healing to occur, the diabetes
mouse may not be an ideal model for study of
matrix metalloproteinase involvement in human
chronic wound healing. Key words: acute/chronic/
MMPs. J Invest Dermatol 119:91±98, 2002
W
ound healing is a complex process involving a
series of overlapping stages, relying on the
collaboration of many different extracellular
matrix components, cell types, and soluble
mediators. For simplicity wound healing is
often segregated into three phases: (i) in¯ammation (early and
late); (ii) re-epithelialization and granulation tissue formation; and
(iii) matrix formation and remodeling (Clark, 1998). If the normal
process of wound healing is disrupted a chronic nonhealing wound
can result. Pressure sores, venous ulcers, and diabetic foot ulcers are
the three main types of such wounds, accounting for 70% of all
chronic wounds (Nwomeh et al, 1998a). In addition to the main
underlying causes, such as ischaemia, neuropathy, and infection for
the diabetic foot ulcers (Watkins, 1998), a number of other factors
can also contribute to the disrupted healing. These include
alterations in growth factor and protease expression (Brown et al,
1989; Cooper et al, 1994; Trengove et al, 1999).
Matrix metalloproteinases (MMPs) are a family of zinc-depend-
ent endopeptidases that collectively degrade nearly all extracellular
matrix and basement membrane proteins at neutral pH. The MMPs
are involved in numerous biologic and pathologic processes, with
their involvement in wound healing being ®rst shown in guinea
pigs (Grillo and Gross, 1967). MMPs are subdivided into ®ve main
classes by structure and substrate speci®city: collagenases, gelati-
nases, stromelysins, membrane-type MMPs (MT-MMPs), and a
nonde®ned set. Although the precise roles that all the MMPs play
during healing remains to be elucidated a number of MMPs have
been characterized in detail. It has been shown that MMP-1
expression is essential for wound re-epithelialization (Parks, 1999);
that MMP-2 is important during angiogenesis (Itoh et al, 1998) and
prolonged matrix remodeling (Parks, 1999); and that MMP-3 is
crucial for normal wound contraction (Bullard et al, 1999).
Within chronic wounds a number of studies have been
performed characterizing the expression of MMPs and TIMPs in
comparison to acute wounds. Chronic wounds have been shown to
possess elevated collagenolytic activity, elevated levels of gelatinases
and stromelysins, and reduced expression of the tissue inhibitors of
MMPs (TIMPS) (Wysocki et al, 1993; Bullen et al, 1995; Vaalamo
et al, 1996, 1997, 1999; Weckroth et al, 1996; Yager et al, 1996;
Nwomeh et al, 1998b, 1999; Saarialho-Kere, 1998; Trengove et al,
1999). Interestingly, however, in studies of ®broblasts derived from
human chronic wounds we have recently shown decreased levels of
MMP-2 activity, resulting from increased TIMP-1 and TIMP-2
production by chronic wound ®broblasts (Cook et al, 2000). The
relationship between MMP activity within these wounds, when
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measured indirectly (wound ¯uid) and directly within the tissues,
clearly requires further investigation.
All these studies point towards the importance of the MMP/
TIMP balance for progression of normal wound repair and indicate
that future wound healing therapies may include modulators of
MMP expression. Such drugs are typically tested on animal models
before entering clinical trials in order to determine their likely
safety and success. The diabetes mouse (C57Bl/ksOlaHsd-db) is an
animal model of type II diabetes that shows impaired dermal
wound healing compared to the nondiabetic (Greenhalgh et al,
1990; Brown et al, 1997). Before treatments can be tested on the
animal models, however, the normal expression pro®les must be
determined to indicate if the model shows a similar pro®le to the
human.
Therefore the aim of the study was to determine the mRNA and
protein expression pro®le of MMP-2, MMP-3, and MMP-9
during dermal wound healing of diabetes and nondiabetic mice. Due
to the limited number of diabetic foot ulcers studied in the
published literature (Trengove et al, 1999; Lobmann et al, 2000) an
additional aim was to determine the MMP expression levels
speci®cally in diabetic foot ulcer ¯uid compared to acute wounds.
This study will enable us to further characterize the diabetes mouse
and so determine if it is a good model for human diabetic foot
ulcers and hence useful for testing future MMP-related wound
therapies.
MATERIALS AND METHODS
Mice Under anesthesia 8±9-wk-old C57Bl/ksOlaHsd-db mice (both
sexes) were shaved and a single 6 mm full thickness excisional wound
was made on each dorsolateral ¯ank. Wounds were covered with
BioClusive (Johnson & Johnson Medical), attached with Vetbond tissue
adhesive (3M), and the mice were housed individually. At de®ned points
(days 1, 3, 5, 7, and 10) after wounding the wound tissue and the
surrounding skin (1 mm from the wound) was collected and processed
for analysis. Wound ¯uid was collected by placing sterile ®lter paper
(Whatman Size 52) on the wound before covering with a dressing. All
work involving mice complied with the local ethical guidelines
established before commencing the study.
Haematoxylin and eosin staining Wound tissue was ®xed overnight
at 4°C in 4% formaldehyde and then dehydrated through an ethanol
series. Wound tissue was then incubated in xylene, followed by a
xylene/wax mix at 60°C under vacuum, and ®nally three separate wax
incubations. The tissue was then oriented in wax and sectioned at 10 mm
with a microtomb. Tissue sections were mounted on Vectabond slides
and incubated at 50°C overnight. Sections were then dewaxed to water,
followed by staining with hemotoxylin and eosin (BDH), and
dehydrated through an ethanol series. Samples were viewed using an
Olympus BX50 microscope and the images were captured and analyzed
using the Lucia 32G/Magic Version 4.11 (Nikon) imaging software.
Wound healing rates Wound closure was determined by using the
initial and ®nal wound areas drawn onto glass slides during the
wounding experiments, with the percentage wound closure calculated as
[(initial ± ®nal)/initial] 3 100. The area of the epidermal tongue was
used to assess the rate of re-epithelialization during wound healing. The
epidermal tongue was classed as the epidermis within the wound up to
the ®rst visible hair follicle, chosen as the arbitrary start of the wound.
The area of granulation tissue was used to assess the rate of granulation
tissue formation during healing, with granulation tissue being determined
as the cell/collagen matrix within the wound up to the ®rst visible hair
follicle.
RNA extraction RNA was isolated from wound tissue using a
combined method of TRIzol reagent (Gibco BRL) and SV total RNA
isolation system (Promega) developed by G. Riley and D. Ireland
(personal communication). RNA concentration and purity was
determined using GeneQuant (Pharmacia) and the integrity was checked
by gel electrophoresis.
Reverse transcription 100 ng of total RNA was used for each 100 ml
reverse transcriptase [50 mM Tris±HCl (pH 8.3), 75 mM KCl, 3 mM
MgCl2 (Promega), 500 mM of each dNTP (Bioline), 10 mM
dithiothreitol (Promega), 50 units of RNase inhibitor (Promega), 2 mg
N6-Random oligonucleotide (Amersham Pharmaceuticals), and 200 units
of M-MLV-RT (Promega)]. The reverse transcriptase was incubated for
60 min at 37°C.
Real-time polymerase chain reaction (PCR) 2.5 ml of the reverse
transcriptase reaction mix was used per 25 ml PCR [1 3 TaqMan
Mastermix (Applied Biosystems), 100 nM TaqMan probe, 200 nm of
each primer]: MMP-2 probe, TCTGTCCTGACCAAGGATATAGC-
CTATTCCTCG; MMP-2 forward primer, AACTACGATGATGA-
CCGGAAGTG; MMP-2 reverse primer, TGGCATGGCCGAACTCA;
MMP-3 probe, AGGTTATCCTAAAAGCATTCACACCCTGGG-
TCT; MMP-3 forward primer, GGAAATCAGTTCTGGGCTATA-
CGA; MMP-3 reverse primer, TAGAAATGGCAGCATCGATCTTC;
MMP-9 probe, TCTGTCCAGACCAAGGGTACAGCCTGTTC;
MMP-9 forward primer, CGAACTTCGACACTGACAAGAAGT;
MMP-9 reverse primer, GCACGCTGGAATGATCTAAGC. The
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) probe and primer
sequences were not provided (Applied Biosystems). The TaqMan PCR
conditions were as follows: 50°C for 2 min, 95°C for 10 min, and then
40 cycles of 95°C for 15 s and 60°C for 1 min. Data were analyzed with
the software provided with the TaqMan. TaqMan Ct values were
converted to arbitrary units by having a standard curve on each plate,
followed by GAPDH normalization. Absolute quanti®cation is possible if
the standard curve utilizes a sample that contains RNA of the target gene
only; however, here the standard contained a mixture of RNA and so
only relative quanti®cation was possible.
Amplicon con®rmation Automative DNA sequencing was
performed on a representative amplicon (ABI Prism, Version 2.1.1) and
the obtained sequence was con®rmed to be the gene of interest by
BLAST search (Altschul et al, 1990).
Protein extraction Wound tissue was homogenized on ice in protein
lysis buffer (50 mM Tris±HCl; 150 mM NaCl; 1% (vol/vol) Triton X-
100; 10 mM CaCl2.2H2O; 0.02% (wt/vol) sodium azide; 10 mg per ml
aprotinin; 1 mg per ml pepstatin A; and 1 mg per ml E64; pH 8.3) and
centrifuged to remove tissue debris. Wound ¯uid protein was extracted
by incubating the ®lter paper for 2 h at room temperature in a protein
lysis buffer. Protein concentration was determined using the bicinchonic
acid (Pearce), following the manufacturer's instructions.
Gelatin zymography Protein samples were assessed for MMP-2 and
MMP-9 by gelatin zymography, according to the method of Heussen
and Dowdle (1980), with 10 mg of nonreduced sample being loaded, per
lane, onto a 7% sodium dodecyl sulfate polyacrylamide gel containing
0.5 mg per ml gelatin.
Western blotting Protein samples were assessed for MMP-3 by
Western blotting according to standard protocols. The primary antibody
was either a sheep antimouse (Dew et al, 2000) or a sheep antihuman
(Allan et al, 1991) MMP-3 polyclonal antibody (in-house) used at 50 mg
per ml for 1 h at room temperature. Sample bands were quanti®ed (for
Western analysis and zymography) using 1D image analysis software
(UVP, Cambridge, U.K.) and expressed as a percentage of the positive
control.
Immunohistochemistry Wound tissue was incubated in 5 mM
monensin in Dulbecco's modi®ed Eagle's medium (Gibco BRL)
supplemented with 10% fetal bovine serum at 37°C for 3 h and then
embedded in OCT (Optimal Cutting Temperature ± Bright). Frozen
tissue was sectioned using a cryostat (Bright) to 10 mm and mounted on
polylysine slides (BDH). Tissue sections were ®xed in 4% formaldehyde
and permeabilized with 0.1% Triton X-100, and nonspeci®c binding of
¯uorescein was blocked with 4-chloro-1-naphthol (2.8 mM in methanol±
phosphate-buffered saline (PBS) with 0.01% H2O2). The primary
antibody [50 mg per ml in-house sheep antimouse MMP-2, MMP-3, or
MMP-9 (Dew et al, 2000)] was added in a PBS solution containing 10%
donkey serum and incubated at room temperature for 1 h. After PBS
washes a ¯uorescein isothiocyanate conjugated donkey antisheep
antibody (Dako, 1:10,000 dilution) was added in PBS for 1 h at room
temperature. Sections were mounted with VectaShield containing DAPI
(Vecta Laboratories). Tissue sections were viewed with a Nikon Eclipse
E800 ¯uorescence microscope and images were captured by CoolSNAP
Version 1,1,0,1 Software (Roper Scienti®c).
Human wound ¯uid Samples of wound ¯uid were obtained with
informed consent from patients with established diabetic wounds
attending the Wound Healing Clinic at the University Hospital of
Wales, Cardiff. Acute wound ¯uid was obtained from patients attending
the same clinic following acute surgical incision. Patients with evidence
of local infection were excluded from the study. Local ethical committee
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approval was obtained for these studies. Chronic wound patients ranged
in age from 55 to 79 y, male and female, with eight type I and ®ve type
II diabetics. Acute wound patients ranged in age from 23 to 41 y, male
and female, with one type I diabetic and eight nondiabetics. During
routine wound assessment sterile ®lter paper was placed on the wound
until saturated with ¯uid. Protein was extracted by incubating the ®lter
paper for 1 h at 4°C in sterile PBS.
Statistical analysis Data were considered to have a parametric
distribution and so a Student's t test (two-tail) assuming unequal variance
was performed for comparisons between in vivo data points. A Student's t
test assuming equal variance was used for in vitro data points.
RESULTS
Healing rates Following wounding an early increase in wound
size was seen for both wild-type and diabetes mice (Fig 1a, day 1),
after which wound closure commenced. For all time points studied,
excluding day 1, nondiabetic mice showed signi®cantly greater
wound closure than their diabetic littermates (Fig 1a). By day 10
nondiabetic mice showed an average wound closure of
81.9% 6 2.8% compared to 45.2% 6 3% in the diabetes mice.
Differences in re-epithelialization became apparent from day 5
onwards (Fig 1b), with a greater epidermal tongue seen in
nondiabetic mice. Day 10 was the only time point studied,
however, that showed a signi®cant difference, with an average
epidermal tongue area of 9 3 104 6 1.5 3 104 mm2 in the
nondiabetic compared to 3.6 3 104 6 4.8 3 103 mm2 in the
diabetes mice. Differences in granulation tissue were only noted
following day 7 (Fig 1c), with an average area of granulation tissue
at day 10 being 152 3 104 6 19.7 3 104 mm2 in the nondiabetic
and 16 3 104 6 2.5 3 104 mm2 in the diabetes mice. Differences
in closure, re-epithelialization, and granulation tissue formation
were seen most dramatically in day 10 wound sections (Fig 1d, e).
Skin sections also highlighted differences in skin thickness, with
nondiabetic mice possessing less adipose tissue (164 6 14 mm) but
thicker dermis (260 6 23 mm) compared to their diabetic
littermates (828 6 42 mm and 131 6 9 mm, respectively).
MMP-2 Real-time quantitative reverse transcription PCR
(RT-PCR) was used to generate a time course of MMP-2
mRNA expression during murine healing (Fig 2a). Low
expression was detected for MMP-2 mRNA during the early
stages of repair with a gradual increase following day 3 being seen
for the nondiabetic samples. Diabetic derived samples showed a
greater increase following day 3 to day 7, after which the increase
ceased. No signi®cant differences were noted for the mRNA
pro®les between mouse types.
Gelatin zymography was used to assess the MMP-2 protein levels
within the wound tissue (Fig 2b) and ¯uid (Fig 2c) samples.
Unwounded skin possessed low basal expression for both mouse
types. Within wound tissue (Fig 2b) pro-MMP-2 levels began to
rise after 3 d for the nondiabetic samples and after 5 d for the
diabetic samples, reaching a maximum at day 7. During the early
stages of healing (days 0±5) the diabetic tissue samples had lower
levels of pro-MMP-2 than nondiabetic samples, but this was only
signi®cant at days 1 and 5. Active MMP-2 levels showed no
signi®cant differences between mouse types, although levels were
lower in unwounded skin and higher at day 10 in diabetic samples.
The low levels of active MMP-2 began to rise after 3 d and reached
a maximum at day 7. The wound ¯uid possessed only pro-MMP-2,
which ¯uctuated around a constant expression level (Fig 2c).
Signi®cant differences were noted at days 3 and 7, with the diabetic
samples being higher at day 3 and lower at day 7. MMP-2
expression was not detected by indirect immuno¯uorescence.
MMP-3 Real-time quantitative RT-PCR was used to generate
a time course of MMP-3 mRNA expression during murine healing
(Fig 3a). Unwounded skin showed low level basal expression. An
increase in nondiabetic mRNA expression was detected following
wounding that remained constant until day 7, after which a minor
increase was seen to day 10. Diabetic samples showed a similar
increase following wounding, and then a minor decline, after
which a constant increase in expression was seen up to day 10.
Although expression was generally higher for diabetic samples than
nondiabetics, no signi®cant differences were noted.
Western blotting was used to assess the MMP-3 protein levels
within wound tissue (Fig 3b) and ¯uid (Fig 3c) samples.
Unwounded skin possessed a low-level basal expression for both
Figure 1. Murine wound healing rates. The wound area was
measured at the start and end of the wounding experiment and used to
calculate the rate of wound closure (a). Tissue sections for each time
point were also analyzed to determine the epidermal tongue area (b) and
granulation tissue area (c). Each point represents the mean 6 SEM.
Signi®cant differences are indicated by an asterisk (p < 0.05). n = 10 for
each point in (a) and n = 8 for each point in (b) and (c). Haemotoxylin
and eosin stained tissue sections of nondiabetic (d) and diabetes (e) mouse
day 10 wounds are also shown. Scale bar: 200 mm. a, adipose tissue; d,
dermis; e, epidermis; gt, granulation tissue.
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mouse types; however, no active MMP-3 was detected in any of
the tissue samples. Following wounding expression levels increased
in both mouse types; however, nondiabetic samples showed a
decline and subsequent increase around day 5, with a further
decline following day 7. The diabetic samples showed a gradual
increase to day 7, followed by a decline mirroring that of the
nondiabetics.
Unlike wound tissue, active MMP-3 was detected in the wound
¯uid samples (Fig 3c). At early time points following wounding
MMP-3 expression was high, after which levels declined to day 5
and then rose again to day 10. Pro-MMP-3 was the exception,
with levels dropping after day 7. As seen for MMP-2, the active
form was consistently lower than that of the proenzyme, with
nondiabetic day 10 being the exception, as both the pro and active
forms possessed similar expression levels. Due to the low expression
level of pro-MMP-3 in the nondiabetic samples, the diabetic day
10 pro-MMP-3 value was signi®cantly higher. The only other
signi®cant difference between diabetic and nondiabetic samples was
at day 1 where nondiabetic samples had higher active MMP-3
levels.
Indirect immuno¯uorescence was used to localize MMP-3
protein within wounded tissue during the early stages of repair
(Fig 4a, b). Due to low expression no MMP-3 was detected in
unwounded skin (Fig 4a). Following wounding, however, MMP-
3 positive staining was detected directly under the basal
keratinocytes, slightly back from the wound edge (Fig 4b).
MMP-3 localization was identical on days 1 and 3 and between
the two mouse types. No staining was detected within the
corresponding negative controls (Fig 4e).
MMP-9 Real-time quantitative RT-PCR was used to generate
a time course of MMP-9 mRNA expression during murine healing
(Fig 5a). MMP-9 mRNA was undetectable in unwounded skin for
either mouse type. Following wounding MMP-9 mRNA
expression was detected, with maximal expression being seen at
day 3 for nondiabetic samples and day 5 for diabetic samples. By
day 10, however, the mRNA levels for both mouse types had
returned to that of day 1. No signi®cant differences were noted
between the mouse types.
Figure 2. MMP-2 mRNA and protein expression pro®les during
wound repair. Real-time RT-PCR was performed on all samples and
the MMP-2 mRNA time course was generated after the values had been
normalized for GAPDH (a). Gelatin zymography was performed on all
protein samples, quanti®ed by 1D image analysis software and expressed
as a percentage of the positive control. The wound tissue pro®le is
shown in (b) and the wound ¯uid pro®le in (c). Each point represents
the mean 6 SEM. Signi®cant differences are indicated by an asterisk
(p < 0.05). n = 6 for each point in (a) and n = 10 for each point in (b)
and (c).
Figure 3. MMP-3 mRNA and protein expression pro®les during
wound repair. Real-time RT-PCR was performed on all samples and
the MMP-3 mRNA time course was generated after the values had been
normalized for GAPDH (a). Western blotting was performed on all
protein samples, quanti®ed by 1D image analysis software and expressed
as a percentage of the positive control. The wound tissue pro®le is
shown in (b) and the wound ¯uid pro®le in (c). Each point represents
the mean 6 SEM. Signi®cant differences are indicated by an asterisk
(p < 0.05). n = 6 for each point in (a) and n = 10 for each point in (b)
and (c).
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Gelatin zymography was used to assess the MMP-9 protein levels
within the wound tissue (Fig 5b) and ¯uid (Fig 5c) samples. No
MMP-9 protein was detected in unwounded skin for either mouse
type (Fig 5b). Wound tissue did not show any active MMP-9
expression. Following wounding a rapid increase in pro-MMP-9
was noted in both mouse types, although a decline occurred sooner
in nondiabetic samples, making days 5 and 7 signi®cantly lower
than the diabetic samples. Wound ¯uid showed a similar pro®le to
that of the wound tissue, with the addition of low levels of active
MMP-9 being detected at day 10 for both mouse types.
Indirect immuno¯uorescence was used to localize MMP-9
protein within wounded tissue during the early stages of repair
(Fig 4c, d). No MMP-9 expression was detected in unwounded
skin; however, after wounding localization was noted in all samples
studied and did not differ between mouse types. At day 1 MMP-9
staining was diffuse, decreasing in intensity further away from the
wound (Fig 4c), whereas at day 3 the staining was more
concentrated along the wound edge, with only minor staining
being seen away from the wound (Fig 4d). No staining was
detected within the corresponding negative controls (Fig 4e).
Human wound ¯uid Wound ¯uid obtained from chronic
wounds in human diabetic patients and acute wounds was analyzed
by zymography and Western blotting (Fig 6). For MMP-2 chronic
wounds showed elevated levels of both pro and active forms
(Fig 6a), with the pro form being expressed at a higher level and
showing signi®cant differences between wound types. For MMP-3
no signi®cant differences were noted between wound types,
although the pro was greater than the active form (Fig 6b). For
MMP-9 three major forms were noted by zymography: a pro, a
135 kDa, and a 260 kDa form. All three forms showed the same
pro®le when comparing between wound types, with chronic
wounds showing lower levels, although this was only signi®cant for
the 135 kDa form.
DISCUSSION
This work has provided a detailed analysis of the expression and
localization of MMP-2, MMP-3, and MMP-9 during skin wound
healing in normal and diabetic mice, and then assessed the
relationship between data obtained from the mouse model with
observations on ¯uid from chronic and acute human wounds. A
signi®cant observation that has emerged from the expression
pro®les of the MMPs during murine wound healing is that the
RNA and protein pro®les correlate poorly. One explanation may
be the differences in stability and degradation rates between the
mRNA and protein. Arumugam et al (1999) have also noted the
RNA/protein differences for MMPs and attributed it to the strict
manner of protein synthesis, secretion, and activation. This study
has also shown a high degree of discrepancy between the two
sources of protein (tissue and ¯uid). Although wound ¯uid is the
typical source of wound protein studied, the validity of using
chronic wound ¯uid to sample protease activity within the chronic
wound environment has, itself, been questioned; wound ¯uid does
not necessarily re¯ect tissue levels of proteinases (Ashcroft et al,
1997b). Moreover, tissues may give the most accurate results for
MMP-2 due to binding to the cell surface during activation
(Knauper and Murphy, 1998) and binding to matrix components
(Davis et al, 1998). Arumugam et al (1999) highlighted this, stating
that as MMPs (and plasminogen activators) are cell and matrix
Figure 4. Localization of MMPs within the murine wound. Indirect immuno¯uorescence for MMP-3 and MMP-9 were performed on 10 mm
tissue sections of diabetes and nondiabetic mouse wounds and unwounded skin. (a) Unwounded nondiabetic MMP-3 stained tissue section. Scale
bar: 50 mm. (b) Day 1 nondiabetic MMP-3 stained tissue section. (c) Day 1 nondiabetic MMP-9 stained tissue section. (d) Day 3 nondiabetic MMP-9
stained tissue section. (e) Day 1 negative control. Arrow, tip of the epidermal tongue; green, positive FITC staining; blue, DAPI nuclear counter stain.
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associated it is important to study tissue rather than ¯uid. These and
previous data (Cook et al, 2000) suggest that local production and
activation of MMPs within the tissues may be more relevant to our
understanding of the pathogenesis of chronic wounds.
The predominant wound cell type expressing MMP-2 is the
®broblast (Madlener, 1998; Parks, 1999; Inkinen et al, 2000).
MMP-2 is believed to be important during angiogenesis (Itoh et al,
1998) and for the generation of matrix fragments that act as a
scaffold for cell migration and a chemotactic signal (Clark, 1998).
As the diabetes mouse possessed signi®cantly reduced pro-MMP-2
levels during healing this may be contributing to the impaired
healing by delaying cell migration and angiogenesis. In support of
this notion it has been shown that ®broblasts from sites that exhibit
preferential healing, i.e., the oral mucosa, exhibit increased
migration and remodeling in association with increased MMP-2
activity (Stephens et al, 2001).
In human and mouse, MMP-3 is primarily expressed by
keratinocytes slightly removed from the wound and involved in
remodeling the basement membrane (Saarialho-Kere et al, 1994;
Madlener et al, 1998; Parks et al, 1998; Lund et al, 1999; Pilcher et
al, 1999), with the immunohistochemistry data presented here
supporting this. Using the MMP-3 knockout mouse Bullard et al
(1999) have also shown that MMP-3 is crucial for wound
contraction apparently through a network of cells that surround
the wound that contains a highly organized actin network. The
MMP-3 ±/± mice lacked this organized actin network. Although
no differences were noted for the mRNA or tissue protein, diabetic
wound ¯uid possessed signi®cantly reduced active MMP-3 at day 1
that may be contributing to impaired healing in a similar manner to
that described by Bullard et al (1999). Additionally, the elevated
pro-MMP-3 of day 10 in the diabetic wound ¯uid may be
impairing healing by maintaining a high level of proteolysis. This
difference is not observed for the active form; however, this could
be due to rapid clearance of activated MMPs and may also account
for why the pro-MMP is always the predominant form during
analysis. This has also been seen in other studies, including that of
Walakovits et al (1992) on MMP expression in synovial ¯uid.
The monocyte/macrophage is the main MMP-9 expressing cell
within the wound, with neutrophils also being known to store but
not synthesize it (Stahle-Backdahl and Parks, 1993). Previous
Figure 5. MMP-9 mRNA and protein expression pro®les during
wound repair. Real-time RT-PCR was performed on all samples and
the MMP-9 mRNA time course was generated after the values had been
normalized for GAPDH (a). Gelatin zymography was performed on all
protein samples, quanti®ed by 1D image analysis software and expressed
as a percentage of the positive control. The wound tissue pro®le is
shown in (b) and the wound ¯uid pro®le in (c). Each point represents
the mean 6 SEM. Signi®cant differences are indicated by an asterisk
(p < 0.05). n = 6 for each point in (a) and n = 10 for each point in (b)
and (c).
Figure 6. MMP expression within human acute and chronic
wound ¯uid. Gelatin zymography (MMP-2 and MMP-9) and Western
blotting (MMP-3) was performed on all protein samples, quanti®ed by
1D image analysis software and expressed as a percentage of the positive
control. MMP-2 expression levels are shown in (a), MMP-3 in (b), and
MMP-9 in (c). Each point represents the mean 6 SEM, where n = 13
for the chronic samples and n = 9 for the acute samples, with signi®cant
differences highlighted (*p < 0.05).
96 WALL ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
studies have localized MMP-9 mRNA to basal keratinocytes near
the epidermal migrating front and deep within the granulation
tissue (Madlener et al, 1998; Lund et al, 1999). In this study MMP-9
protein showed greater dermal staining than the previously
published in situ work, although strong staining was seen on day
1 post wounding in similar locations to that of the in situ data. The
dermal/granulation tissue positive staining was probably due to
neutrophil, and later monocyte/macrophage, derived MMP-9. The
precise role of MMP-9 during healing is unclear; however, it may
be involved in keratinocyte detachment from the basement
membrane before migration (Parks et al, 1998; Kahari and
Saarialho-Kere, 1997), and be used to aid matrix digestion by
neutrophils and macrophages during removal of necrotic tissue
(Riches, 1998). Diabetes mice have delayed monocyte recruitment
to the wound (unpublished data) that may be a major contributor
towards the impaired healing. The reduced levels of pro-MMP-9
are probably a re¯ection of this delayed recruitment; however,
whether MMP-9 levels are a cause or effect of this delay requires
further investigation.
The human wound ¯uid data indicate that of the MMPs studied
elevated MMP-2 could be the major cause for the nonhealing
nature of human diabetic foot ulcers. A likely cause for the elevated
levels of MMP-2 is the age of the patients, as those with chronic
wounds had an average age of 64.6 6 2.2 y compared to
29.6 6 2.1 y for acute wound patients. It has previously been
shown that aged subjects possess elevated levels of MMPs and
reduced TIMPs in normal and wounded skin compared to younger
subjects, and this may contribute to their increased risk of
developing chronic wounds (Ashcroft et al, 1997a; 1997b).
Elevated MMP-2 would result in excessive matrix degradation
preventing the normal matrix formation and remodeling and may
result in the formation of a chronic wound. The data from diabetic
wounds presented here support the published data for MMP-2 but
oppose the data for MMP-9 (Wysocki et al, 1993; Bullen et al,
1995; Weckroth et al, 1996; Yager et al, 1996; Ashcroft et al, 1997a,
b; Herouy et al, 1998; Neely et al, 1999; Trengove et al, 1999).
Most reports do not include diabetic wounds, however, and those
that do have limited numbers (n = 3, Trengove et al, 1999), or
focus on other MMPs (Lobmann et al, 2000). Therefore the MMP-
9 differences to previously published data on other wound types
may be due to diabetic complications not seen in these nondiabetic
patients with chronic wounds. For example, hyperglycaemia, either
alone or in conjunction with matrix glycation, has previously been
shown to reduce MMP-9 levels in mesangial cells in vitro (Anderson
et al, 1996; McLennan et al, 1998). Additionally, other complica-
tions, such as altered cytokine expression (Desfaits et al, 1998), may
also alter MMP expression within the diabetic wound.
The diabetes mouse did not show similar alterations in MMP
expression to those of the human condition, with a number of
potential reasons for this: species, wound position, and blood
glucose regulation. Additionally, wound duration is a major factor
for chronic wounds, often being over a year. However wound
duration was shorter in the diabetes mouse. Finally bacterial content
is relevant: any infected mice were omitted from the study, whereas
the majority of human chronic wounds are infected, even if
clinically noninfected (Davies et al, 2001). This would be a major
factor contributing to the differences between mouse and human as
bacterial products induce and activate MMP-2 (Firth et al, 1997;
Okamoto et al, 1997; Maeda et al, 1998; Lopez-Boado et al, 2000).
Therefore the diabetes mouse is better classed as an animal model of
impaired acute wound healing in diabetics rather than of chronic
wounds. Although the mouse model may be an unfavorable choice
for testing wound therapies involving MMP modulation it can be
used for a number of other studies. These would include
investigating the potential factors that are causing elevated levels
of MMPs within human wounds by modulating the bacterial
content and glucose levels of the mouse.
In conclusion, a number of studies have shown altered MMP
expression in chronic compared to acute wounds; however, little
has been done to characterize animal models in a similar manner
and thus determine their usefulness. In this study we have expanded
the current knowledge of the diabetes mouse by showing that, in
addition to a delay in wound closure, impairment in re-
epithelialization and granulation tissue formation occurs.
Additionally MMPs show an altered expression pro®le during the
early stages of healing and differences occur between the diabetes
and nondiabetic mice that may be contributing to the differences in
healing. Not all of the MMPs studied show comparable results to
the data obtained from human wound ¯uid, however. Therefore,
although clearly showing the importance of MMP regulation for
normal healing, and providing an excellent model for impaired
acute wound healing, the diabetes mouse may not be ideal for
studying MMP-dependent therapies for chronic human wounds.
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